An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice.
The efficacy and tolerability of fluconazole given as a single oral dose of 150 mg were assessed in 1,017 patients in general practice presenting with signs and symptoms of vaginal candidiasis. At the review visit 7-14 days after treatment, about 95 per cent of patients reported being either cured or improved. High vaginal swabs taken from 43 patients out of 50 who failed following treatment revealed Candida albicans in 17 (1.8 per cent). Efficacy in patients with predisposing factors (oral contraceptives, antibiotics and recurrent vaginal candidiasis - four episodes or more in previous year) was not significantly different from that in those without these factors. Of patients who had received previous intravaginal therapy for vaginal candidiasis, 88 per cent preferred fluconazole, 10 per cent previous therapy and two per cent had no preference. Investigators assessed efficacy after fluconazole as excellent or good in 91 per cent and tolerability as excellent or good in 91 per cent of patients. Significant adverse effects were reported in less than one per cent of patients.
Pfizer Ltd, Sandwich, Kent.
R J
RJ
Phillips
S A
SA
Watson
F F
FF
McKay
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005194:Family Practice; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged
D015725:Fluconazole